Primary mediastinal large B-cell lymphoma

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →

At a Glance

Live from database

1FDA treatments

10Recruiting trials

Regulatory Watchboard

10 events

May 2026Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy

Fondazione Italiana Linfomi - ETS

TrialNOT YET RECRUITING

Nov 2024Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL

Sun Yat-sen University — PHASE2

TrialRECRUITING

Oct 2024CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas

University of Maryland, Baltimore — PHASE1

TrialENROLLING BY INVITATION

Sep 2024Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma

St. Petersburg State Pavlov Medical University — PHASE1, PHASE2

TrialENROLLING BY INVITATION

Jun 2024Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Allogene Therapeutics — PHASE2

TrialRECRUITING

Jun 2024A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment

Sun Yat-sen University — PHASE2

TrialNOT YET RECRUITING

Feb 2023Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma

Memorial Sloan Kettering Cancer Center — PHASE1

TrialACTIVE NOT RECRUITING

Jan 2023ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Acepodia Biotech, Inc. — PHASE1

TrialRECRUITING

Jun 2022Primary Mediastinal Large B-cell Lymphoma With CNS Involvement

IRCCS San Raffaele

TrialACTIVE NOT RECRUITING

Apr 2022Bio-CAR-T BS Study

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for Primary mediastinal large B-cell lymphoma.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

Breyanzi

(lisocabtagene maraleucel)Orphan drugstandard

Juno Therapeutics, Inc.

12.1 Mechanism of Action BREYANZI is a CD19-directed genetically modified autologous cell immunotherapy administered as a defined composition to reduc...

View full treatment details on disease page →

Clinical Trial Landscape

10 active trials

1Phase 3

2Phase 2

3Phase 1

1N/A

3Unknown

10Total recruiting

Search clinical trials for Primary mediastinal large B-cell lymphoma →

Recent News & Research

No recent news articles indexed yet for Primary mediastinal large B-cell lymphoma.
Search PubMed for Primary mediastinal large B-cell lymphoma →

Browse all Primary mediastinal large B-cell lymphoma news →

Specialist Network

Top 6 by expertise

Alex F Herrera

City of Hope Medical Center

Score 327 trials

Mitchell Cairo, MD, MD

New York Medical College

📍 HAWTHORNE, NY

Score 2011 trials

Ajay Gopal

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

📍 SEATTLE, WA

Score 1814 trials

Mengyang Di, MD, PhD, MD

Fred Hutch/University of Washington Cancer Consortium

📍 SEATTLE, WA

Score 162 trials

Jae Park, MD

Memorial Sloan Kettering Cancer Center

Score 1213 trials

Study Official

Genmab

Score 99 trials

View all Primary mediastinal large B-cell lymphoma specialists →

Quick Actions

View Disease Page

Full profile, treatments, community

Search Clinical Trials

Find recruiting studies now

Find Specialists

Ranked by expertise & trials

Financial Assistance

Copay cards, PAPs, grants

Latest News

Research, approvals & updates

Browse All Diseases

11,000+ rare disease profiles